Recce Pharmaceuticals Ltd (ASX: RCE) Share Price and News

Mr Graham has a background in marketing, business development and commercialisation of early-stage technology with global potential. Mr Graham continues to work with the growth and direction of Company, routinely investing alongside shareholders in capital rounds to date. He is member of Risk Management Committee.

Mr McKeough has experience in a variety of private and listed corporations across many sectors, including professional services, technology, financial services, charities, health, biotech, child care and education. He recently stepped down as Managing Director of a legal practice specialising in equity capital markets and advice to listed companies and as part of the senior leadership team at share registry, Automic Group. He is Chairman of Risk Management Committee.

Dr Dunton has held positions at biotechnology and pharmaceutical companies including serving as president and chief executive officer at Panacos Pharmaceuticals, Inc., Metaphore Pharmaceuticals, Inc., and chief operating officer at Emisphere Technologies, Inc. Dr Dunton served in several positions at Johnson and Johnson including president and managing director at the Janssen Research Foundation where he was responsible for leading over 2,000 professionals worldwide and prior to this as vice president of global clinical research and development at the R.W. Johnson Pharmaceutical Research Institute. During his career, Dr Dunton has been responsible for the approval of approximately 20 New Drug Applications; an amalgamation of prescription and OTC products. He is member of Risk Management Committee and directorships held in other listed entities during the last three years were with Palatin Technologies, Inc. (NYSE: PTN), Oragenics, Inc. (NYSE: OGEN), CorMedix, Inc. (NYSE: GRMD),Regeneus Ltd (ASX: RGS).

Ms Dilizia had a executive career in public relations and marketing for a retail chain. Ms Dilizia was a market research consultant, which included marketing development of health-care and pharmaceutical products

Dr Prendergast is currently Non-Executive Chairman and Co-Founder of Palatin Technologies developing targeted therapeutics for the treatment of diseases with unmet medical need and Director of Nighthawk Biosciences, Inc., a publicly traded, clinical stage immunomodulatory company. He was previously a member of the board of the life science companies, Avigen, AVAX Technologies and MediciNova Inc and also as a member of the Advisory Board for the Institute for the Biotechnology of Infectious Diseases (IBID) at the University of Technology Sydney, now called the ithree Institute. Prior to that he was a Managing Director of The Castle Group Ltd., a New York medical venture capital firm. Dr Prendergast held Post-Doctoral Fellowships in the Department of Biochemistry and Molecular Biology, Harvard University and at the Center for Research on Blood Diseases in Paris with Professor Jean Dausset (Nobel Prize, 1980). During his career, Dr Prendergast has been responsible for the approval of three New Drug Applications. He is member of risk management committee. Directorships held in other listed entities during the last three years includes Heat Biologics, Inc. (NASDAQ: HTBX).

Dr Ward has specialisation in pharmaceutical quality management and product development. Before Recce Pharmaceuticals, he held a technical speciality and special project leadership role with Pfizer Pharmaceuticals, involving providing data for the regulatory submissions to the FDA and TGA. After Pfizer, he was the Laboratory Manager for Solbec, involving, again as presently, drug specifications and pharmaceutical trials for the ASX-Listed company. Most recently, he was Quality Manager at Phebra and responsible for product quality and release of all drugs of the company with the TGA.

-

-

-

-

-

-